Chronic Kidney Disease of Unknown Etiology

González-Quiroz, Marvin; García, Pablo; Anand, Shuchi

doi:10.1007/978-3-030-93438-5_17

Tubulointerstitial Nephritis 2022

DOI: 10.1007/978-3-030-93438-5_17

|View full text |Cite

Chronic Kidney Disease of Unknown Etiology

Marvin González-Quiroz

Pablo García

Shuchi Anand

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have concluded that drug-induced QT interval prolongation is mainly due to the inhibition of potassium ion channels on the cardiomyocyte membrane. [20] Other studies have shown that EGFR-TKIs have a regulatory effect on potassium ion channels. [21−23] Additional findings have suggested that osimertinib has a weak inhibitory effect on the cardiac potassium ion channel Kv11.1, which is encoded by human ether-àgo-go-related gene (hERG) with an in vitro IC50 of 0.69 μm.…”

mentioning

confidence: 99%

Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report

GUO¹,

Luo²,

ZHU³

et al. 2023

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

O simertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), is approved globally as the first-line treatment for patients with EGFR mutations (EGFRm: Ex19del/L858R) and T790M resistance mutations in advanced non-small cell lung cancer (NSCLC). [1−3] With its widespread use, the cardiotoxicity of osimertinib has been of great concern. According to the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS), the main cardiac-related adverse events with EGFR-TKIs are heart failure, QT prolongation, atrial fibrillation, acute myocardial infarction and pericardial effusion, and osimertinib has a higher incidence of QT prolongation, heart failure and atrial fibrillation than other EGFR-TKIs. [4] As mentioned in its package insert, a decline in left ventricular ejection fraction (LVEF) of > 10% from baseline and to less than 50% of LVEF occurred in 3.2% of patients following osimertinib treatment in clinical trials, 0.8% of patients were found to have a heart rate corrected QT interval (QTc) of > 500 ms, and 3.1% of patients had a QTc increase from baseline of > 60 ms. No QTc-related arrhythmias were reported. [5] This is an 81-year-old male patient whose medical history is shown in Figure 1. Eight months ago, two nodules (LU-RADS class 4) in the left upper lung were revealed by CT scan at physical examination, located in the posterior apical segment and the lingual segment (Figure 2A). The patient presented with left-side chest pain and an electrocardiogram suggestive of lateral wall myocardial ischemia (Figure 2B). Accordingly, he underwent coronary angiography, the results of which showed 50% stenosis in the proximal segment of the left anterior descending bra-

show abstract

mentioning

confidence: 99%

Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report

GUO¹,

Luo²,

ZHU³

et al. 2023

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chronic Kidney Disease of Unknown Etiology

Cited by 1 publication

References 51 publications

Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report

Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report

Contact Info

Product

Resources

About